Compassionate Use Protocol for the Treatment of Autoinflammatory Syndromes

Expanded access is currently available for this treatment.
Verified January 2014 by Eli Lilly and Company
Sponsor:
Information provided by (Responsible Party):
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT01724580
First received: November 5, 2012
Last updated: January 24, 2014
Last verified: January 2014
  Purpose

The Requesting Physician/Investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the compassionate use program.


Condition Intervention
Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature (CANDLE)
Juvenile Dermatomyositis (JDM)
Drug: Baricitinib

Study Type: Expanded Access     What is Expanded Access?
Official Title: Compassionate Use Treatment Protocol I4V-MC-JAGA: Treatment of Conditions Expected to Benefit From JAK 1/2 Inhibition: CANDLE, CANDLE-Related Conditions, and Severe Juvenile Dermatomyositis

Resource links provided by NLM:


Further study details as provided by Eli Lilly and Company:

Study Start Date: October 2011
Estimated Study Completion Date: December 2020
Estimated Primary Completion Date: December 2020 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Baricitinib
    Administered orally
    Other Names:
    • LY3009104
    • INCB 028050
  Eligibility

Ages Eligible for Study:   18 Months and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Are ≥17.5 months of age. Participants younger than 17.5 months of age can be considered for enrollment after discussion with the sponsor
  • Have systemic signs and symptoms of inflammation as manifested by the presence of two or more of the following symptoms: rash, fever, musculoskeletal pain, headache, fatigue or weakness
  • Have a Diary Score of ≥0.5 (CANDLE Diary) or ≥1.0 (JDM Diary) assessed over 2 weeks prior to entry, if available. Otherwise, participants can complete the diary after study consent is signed during the screening period and meet the inclusion criteria for enrollment into the study
  • Are ≥8.5 kilogram (kg) in body weight. Participants weighing less than 8.5 kg can be considered for enrollment after discussion with the sponsor
  • Have been previously treated with at least 1 biologic therapy and, in the opinion of the investigator, did not respond or are no longer responding to therapy. If the participant has been diagnosed with CANDLE or Nakajo-Nishimura Syndrome (NNS) or an equivalent syndrome, the need for previous biologic therapy is not required
  • Require treatment with oral corticosteroids (≥0.15 milligram per kilogram [mg/kg] of prednisone or its equivalent) for control of systemic signs and symptoms of their autoinflammatory disease for at least 2 weeks prior to study entry
  • Have had previous documented elevations in acute-phase reactants (for example, high sensitivity C-Reactive protein [hsCRP]) considered to be the result of the autoinflammatory disease
  • Have the ability to provide informed consent or have legal representative who is willing and able to provide written informed consent, provided that assent is obtained from participants at an age-appropriate level

Exclusion Criteria:

  • Have received an immunosuppressive biologic agent/monoclonal antibody within 4 half-lives prior to entry, for example, anakinra (4 half-lives=18 hours); etanercept (4 half-lives=18 days); infliximab; adalimumab (4 half-lives=36 days); use of intravenous immune globulin (IVIg) is permitted
  • Are pregnant or nursing at the time of entry
  • Are females of childbearing potential (women >12 or who have had at least 1 menstrual period regardless of age) who are sexually active and who do not agree to use 2 forms of highly effective methods of birth control or remain abstinent during the study and for at least 28 days following the last dose of investigational product
  • Are sexually active males who do not agree to use 2 forms of highly effective birth control with female partners of childbearing potential or remain abstinent during the study and for at least 28 days following the last dose of investigational product
  • Have had symptomatic herpes zoster or herpes simplex infection within 12 weeks prior to entry or during the screening period
  • Have a history of disseminated/complicated herpes zoster (for example, multidermatomal involvement, ophthalmic zoster, central nervous system [CNS] involvement, postherpetic neuralgia)
  • Have evidence of active infection, at the time of entry or during the screening period
  • Have a history of active hepatitis B (HBV), hepatitis C (HCV), or human immunodeficiency virus (HIV) infection
  • Have documented high titer autoantibodies suggestive clinically of autoimmune diseases other than severe JDM
  • Are immunocompromised and, in the opinion of the investigator, are at an unacceptable risk for participating in the study
  • Have had a serious systemic or local infection (including an infectious mononucleosis-like illness or herpes zoster) within 12 weeks prior to entry or during the screening period
  • Have been exposed to a live vaccine within 12 weeks prior to entry or are expected to need/receive a live vaccine (including herpes zoster vaccination) during the course of the study Note: Investigators should review the vaccination status of the participants and follow the local guidelines for vaccination with nonlive vaccines intended to prevent infectious disease prior to entering participants into the study
  • Have had household contact with a person with active tuberculosis (TB) and did not receive appropriate and documented prophylaxis for TB
  • Have a serious and/or unstable illness that, in the opinion of the investigator, poses an unacceptable risk for the participant's participation in the study
  • Have an estimated glomerular filtration rate (eGFR) based on the most recent available serum creatinine of <40 milliliters per minute (mL/min)
  • Have or have had a history of lymphoproliferative disease; or signs or symptoms suggestive of possible lymphoproliferative disease, or active primary or recurrent malignant disease; or been in remission from clinically significant malignancy for <5 years Note: Participants with resolved cervical dysplasia, or no more than 3 successfully treated basal-cell carcinoma of the skin, may participate in this study
  • Have a history of chronic alcohol abuse or intravenous (IV) drug abuse within the 2 years prior to entry
  • Are unable or unwilling to make themselves available for the duration of the study and/or are unwilling to follow study restrictions/procedures
  • Are currently enrolled in, or discontinued within the last 30 days from a clinical trial involving an investigational product or non-approved use of a drug or device (other than the investigational product used in this study), or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01724580

Contacts
Contact: There may be multiple sites in this compassionate use trial. 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559

Locations
United States, Maryland
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Bethesda, Maryland, United States, 20892
Contact: Eli Lilly         
Sponsors and Collaborators
Eli Lilly and Company
Investigators
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company
  More Information

No publications provided

Responsible Party: Eli Lilly and Company
ClinicalTrials.gov Identifier: NCT01724580     History of Changes
Other Study ID Numbers: 14559, I4V-MC-JAGA
Study First Received: November 5, 2012
Last Updated: January 24, 2014
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Dermatomyositis
Fever
Lipodystrophy
Skin Diseases
Sweet Syndrome
Myositis
Muscular Diseases
Musculoskeletal Diseases
Polymyositis
Neuromuscular Diseases
Nervous System Diseases
Connective Tissue Diseases
Body Temperature Changes
Signs and Symptoms
Skin Diseases, Metabolic
Lipid Metabolism Disorders
Metabolic Diseases
Erythema

ClinicalTrials.gov processed this record on April 17, 2014